KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Amortization of Deferred Charges: 2011-2024

Historic Amortization of Deferred Charges for Esperion Therapeutics (ESPR) over the last 12 years, with Dec 2024 value amounting to $1.5 million.

  • Esperion Therapeutics' Amortization of Deferred Charges rose 924.61% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 million, marking a year-over-year increase of 421.23%. This contributed to the annual value of $1.5 million for FY2024, which is 11.73% down from last year.
  • Esperion Therapeutics' Amortization of Deferred Charges amounted to $1.5 million in FY2024, which was down 11.73% from $1.7 million recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' Amortization of Deferred Charges registered a high of $1.7 million during FY2020, and its lowest value of $1.5 million during FY2024.
  • For the 3-year period, Esperion Therapeutics' Amortization of Deferred Charges averaged around $1.6 million, with its median value being $1.6 million (2022).
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first rose by 4.69% in 2023, then fell by 11.73% in 2024.
  • Esperion Therapeutics' Amortization of Deferred Charges (Yearly) stood at $1.7 million in 2020, then dropped by 6.89% to $1.6 million in 2021, then remained steady at $1.6 million in 2022, then grew by 4.69% to $1.7 million in 2023, then dropped by 11.73% to $1.5 million in 2024.